http://www.shinfield-pharma.com/european-commission-grants-orphan-drug-designation-to-soliris-eculizumab-for-the-treatment-of-patients-with-myasthenia-gravis-mg/ 2014-08-30T13:56:16+00:00 http://www.shinfield-pharma.com/wp-content/uploads/2014/08/600x340_1.jpg http://www.shinfield-pharma.com/european-medicines-agency-accepts-marketing-authorization-application-for-asfotase-alfa-as-a-treatment-for-patients-with-hypophosphatasia/ 2014-08-30T13:56:06+00:00 http://www.shinfield-pharma.com/wp-content/uploads/2014/08/600x340_2.jpg http://www.shinfield-pharma.com/fda-approves-conversion-of-soliris-eculizumab-accelerated-approval-in-ahus-to-regular-approval-for-the-treatment-of-patients-with-ahus/ 2014-08-30T13:39:30+00:00 http://www.shinfield-pharma.com/wp-content/uploads/2014/08/coffee-beans.jpg http://www.shinfield-pharma.com/breaking-world-pharma-news/ 2014-11-20T15:13:36+00:00 http://www.shinfield-pharma.com/wp-content/uploads/2014/08/coffee-beans.jpg http://www.shinfield-pharma.com/fda-warns-consumers-about-fraudulent-ebola-treatment-products/ 2014-11-20T15:03:54+00:00 http://www.shinfield-pharma.com/wp-content/uploads/2014/11/fraudulent-drugs.jpg http://www.shinfield-pharma.com/wp-content/uploads/2014/11/fraudulent-drugs-300x170.jpg http://www.shinfield-pharma.com/article-england-could-lose-16000-gps/ 2014-11-20T15:15:04+00:00 http://www.shinfield-pharma.com/wp-content/uploads/2014/11/doctor-patient.jpg http://www.shinfield-pharma.com/understanding-myasthenia-gravis-symptoms-diagnosis-and-treatment-options/ 2026-08-04T14:32:22+00:00